RxDoctor Payments Data

Kenneth Rucker, MD

Internal Medicine · Durand, WINPI 1326088642

Payments from drug & device makers

$3,129in general payments, 2019–2025

Across 209 payments — averaging $14.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$929
  • Boehringer Ingelheim$662
  • Amgen$285
  • Pfizer$204
  • Novartis$185
  • Novo Nordisk$172
  • plus $692 from 15 others

What the payments were for

  • Food & beverage$3,118100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,129 in reported general payments places this provider in the 90th percentile of 1,411 internal medicine providers in Wisconsin.

See all internal medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$17,384
Medicare patients
110
Services billed
537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban232$157,060
TrulicityDulaglutide62$61,439
JardianceEmpagliflozin70$41,151
XareltoRivaroxaban62$32,235
OzempicSemaglutide24$22,958
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$15,724
Incruse ElliptaUmeclidinium Bromide39$13,943
MyrbetriqMirabegron25$12,025
MounjaroTirzepatide11$11,595
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,399
SymbicortBudesonide/Formoterol Fumarate34$7,886
ArexvyRsvpref3 Antigen/As01e/Pf26$7,779
Breo ElliptaFluticasone/Vilanterol15$6,472
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$6,417
Levemir FlexpenInsulin Detemir29$4,818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$204$157,060232 claims
Lilly USA, LLCTrulicity, Mounjaro$65$73,03373 claims
Boehringer IngelheimJardiance$662$41,15170 claims
GSKIncruse Ellipta, Trelegy Ellipta, Arexvy, Breo Ellipta$23$36,59393 claims
Johnson & JohnsonXarelto$145$32,23562 claims
AstraZenecaBreztri Aerosphere, Symbicort$43$23,61059 claims
Novo NordiskOzempic$172$22,95824 claims
Astellas Pharma US IncMyrbetriq$16$12,02525 claims
AbbVieLumigan, Combigan$929$5,48222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,411 internal medicine providers in Wisconsin.

Other internal medicine in Durand

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →